TW201813967A - 磷脂醯肌醇3－激酶δ及γ之新穎雙重抑制劑 - Google Patents

Info

Publication number

TW201813967A

TW201813967A TW106132359A TW106132359A TW201813967A TW 201813967 A TW201813967 A TW 201813967A TW 106132359 A TW106132359 A TW 106132359A TW 106132359 A TW106132359 A TW 106132359A TW 201813967 A TW201813967 A TW 201813967A

Authority

TW

Taiwan

Prior art keywords

methyl

dihydro

isoindole

amino

thiazol

Prior art date

2016-09-22

Links

• Espacenet
• Global Dossier
• Discuss

• 150000003904 phospholipids Chemical class 0.000 title abstract description 7
• 239000003112 inhibitor Substances 0.000 title description 16
• 230000009977 dual effect Effects 0.000 title description 4
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 title 2
• 229940109239 creatinine Drugs 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims abstract description 228
• 150000003839 salts Chemical class 0.000 claims abstract description 75
• 238000000034 method Methods 0.000 claims abstract description 52
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 26
• 208000006673 asthma Diseases 0.000 claims abstract description 24
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 22
• 238000002560 therapeutic procedure Methods 0.000 claims abstract description 12
• 150000001412 amines Chemical class 0.000 claims description 223
• -1 5- {2-[(1 S ) -1-cyclopropylethyl] -7- (methylsulfonyl) -1-oxo-2,3- Dihydro-1 H -isoindole-5-yl} -4-methyl-1,3-thiazol-2-yl Chemical group 0.000 claims description 161
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 81
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 72
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 66
• 239000001301 oxygen Substances 0.000 claims description 66
• 229910052760 oxygen Inorganic materials 0.000 claims description 66
• 125000000217 alkyl group Chemical group 0.000 claims description 33
• 239000003814 drug Substances 0.000 claims description 16
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
• 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims description 12
• 125000001424 substituent group Chemical group 0.000 claims description 10
• 125000005842 heteroatom Chemical group 0.000 claims description 9
• 238000004519 manufacturing process Methods 0.000 claims description 9
• 238000006467 substitution reaction Methods 0.000 claims description 7
• 239000003085 diluting agent Substances 0.000 claims description 6
• 150000003431 steroids Chemical class 0.000 claims description 6
• 239000002671 adjuvant Substances 0.000 claims description 5
• 125000003277 amino group Chemical group 0.000 claims description 5
• 239000005557 antagonist Substances 0.000 claims description 5
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 4
• 239000003795 chemical substances by application Substances 0.000 claims description 4
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
• 229910052739 hydrogen Inorganic materials 0.000 claims description 4
• 239000003149 muscarinic antagonist Substances 0.000 claims description 4
• 229940124750 glucocorticoid receptor agonist Drugs 0.000 claims description 3
• 229940124530 sulfonamide Drugs 0.000 claims description 3
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
• MFYQUMRHYXKIOO-KRWDZBQOSA-N 2-[(1S)-1-cyclopropylethyl]-N-methyl-6-[4-methyl-2-[[6-(4-methyl-2-oxopiperazin-1-yl)pyridin-2-yl]amino]-1,3-thiazol-5-yl]-3-oxo-1H-isoindole-4-sulfonamide Chemical compound C1(CC1)[C@H](C)N1CC=2C=C(C=C(C=2C1=O)S(=O)(=O)NC)C1=C(N=C(S1)NC1=NC(=CC=C1)N1C(CN(CC1)C)=O)C MFYQUMRHYXKIOO-KRWDZBQOSA-N 0.000 claims description 2
• TYTHLOGWHWLWET-RDJZCZTQSA-N 2-[(1S)-1-cyclopropylethyl]-N-methyl-6-[4-methyl-2-[[6-[(2S)-2-methyl-6-oxopiperazin-1-yl]pyridin-2-yl]amino]-1,3-thiazol-5-yl]-3-oxo-1H-isoindole-4-sulfonamide Chemical compound C1(CC1)[C@H](C)N1CC=2C=C(C=C(C=2C1=O)S(=O)(=O)NC)C1=C(N=C(S1)NC1=NC(=CC=C1)N1[C@H](CNCC1=O)C)C TYTHLOGWHWLWET-RDJZCZTQSA-N 0.000 claims description 2
• KRJCGMRLWBVONG-SJORKVTESA-N 2-[(1S)-1-cyclopropylethyl]-N-methyl-6-[4-methyl-2-[[6-[(3R)-3-methyl-2-oxopiperazin-1-yl]pyridin-2-yl]amino]-1,3-thiazol-5-yl]-3-oxo-1H-isoindole-4-sulfonamide Chemical compound C1(CC1)[C@H](C)N1CC=2C=C(C=C(C=2C1=O)S(=O)(=O)NC)C1=C(N=C(S1)NC1=NC(=CC=C1)N1C([C@H](NCC1)C)=O)C KRJCGMRLWBVONG-SJORKVTESA-N 0.000 claims description 2
• YXGZTQDPLYDOCC-RDJZCZTQSA-N 2-[(1S)-1-cyclopropylethyl]-N-methyl-6-[4-methyl-2-[[6-[(5S)-5-methyl-2-oxopiperazin-1-yl]pyridin-2-yl]amino]-1,3-thiazol-5-yl]-3-oxo-1H-isoindole-4-sulfonamide Chemical compound C1(CC1)[C@H](C)N1CC=2C=C(C=C(C=2C1=O)S(=O)(=O)NC)C1=C(N=C(S1)NC1=NC(=CC=C1)N1C(CN[C@H](C1)C)=O)C YXGZTQDPLYDOCC-RDJZCZTQSA-N 0.000 claims description 2
• JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 claims description 2
• 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims description 2
• 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims description 2
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
• UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims 2
• KVKANZTYGYFKQY-INIZCTEOSA-N 2-[(1S)-1-cyclopropylethyl]-5-[4-methyl-2-[[6-(3-methyl-2-oxoimidazolidin-1-yl)pyridin-2-yl]amino]-1,3-thiazol-5-yl]-7-methylsulfonyl-3H-isoindol-1-one Chemical compound C1(CC1)[C@H](C)N1C(C2=C(C=C(C=C2C1)C1=C(N=C(S1)NC1=NC(=CC=C1)N1C(N(CC1)C)=O)C)S(=O)(=O)C)=O KVKANZTYGYFKQY-INIZCTEOSA-N 0.000 claims 1
• PZHYYDQKVVSTEG-KRWDZBQOSA-N 2-[(1S)-1-cyclopropylethyl]-N-ethyl-6-[4-methyl-2-[[6-(2-oxopiperazin-1-yl)pyridin-2-yl]amino]-1,3-thiazol-5-yl]-3-oxo-1H-isoindole-4-sulfonamide Chemical compound C1(CC1)[C@H](C)N1CC=2C=C(C=C(C=2C1=O)S(=O)(=O)NCC)C1=C(N=C(S1)NC1=NC(=CC=C1)N1C(CNCC1)=O)C PZHYYDQKVVSTEG-KRWDZBQOSA-N 0.000 claims 1
• NDSSKUUMDINTDG-HNNXBMFYSA-N 2-[(2S)-butan-2-yl]-N-methyl-6-[4-methyl-2-[[6-(3-oxomorpholin-4-yl)pyridin-2-yl]amino]-1,3-thiazol-5-yl]-3-oxo-1H-isoindole-4-sulfonamide Chemical compound C[C@@H](CC)N1CC=2C=C(C=C(C=2C1=O)S(=O)(=O)NC)C1=C(N=C(S1)NC1=NC(=CC=C1)N1C(COCC1)=O)C NDSSKUUMDINTDG-HNNXBMFYSA-N 0.000 claims 1
• LLUGOCWVLNJQNI-AWEZNQCLSA-N 5-[4-methyl-2-[[6-(2-oxopyrrolidin-1-yl)pyridin-2-yl]amino]-1,3-thiazol-5-yl]-7-methylsulfonyl-2-[(2S)-1,1,1-trifluoropropan-2-yl]-3H-isoindol-1-one Chemical compound CC=1N=C(SC=1C=1C=C2CN(C(C2=C(C=1)S(=O)(=O)C)=O)[C@H](C(F)(F)F)C)NC1=NC(=CC=C1)N1C(CCC1)=O LLUGOCWVLNJQNI-AWEZNQCLSA-N 0.000 claims 1
• VGBZVXNIRCSRBK-AWEZNQCLSA-N N-[6-[[5-[2-[(1S)-1-cyclopropylethyl]-7-methylsulfonyl-1-oxo-3H-isoindol-5-yl]-4-methyl-1,3-thiazol-2-yl]amino]pyridin-2-yl]acetamide Chemical compound C[C@@H](C1CC1)N1CC2=CC(=CC(=C2C1=O)S(C)(=O)=O)C1=C(C)N=C(NC2=CC=CC(NC(C)=O)=N2)S1 VGBZVXNIRCSRBK-AWEZNQCLSA-N 0.000 claims 1
• XDWSNPNGAFALHJ-HNNXBMFYSA-N N-ethyl-6-[4-methyl-2-[[6-(3-oxomorpholin-4-yl)pyridin-2-yl]amino]-1,3-thiazol-5-yl]-3-oxo-2-[(2S)-1,1,1-trifluoropropan-2-yl]-1H-isoindole-4-sulfonamide Chemical compound C(C)NS(=O)(=O)C=1C=2C(N(CC=2C=C(C=1)C1=C(N=C(S1)NC1=NC(=CC=C1)N1C(COCC1)=O)C)[C@H](C(F)(F)F)C)=O XDWSNPNGAFALHJ-HNNXBMFYSA-N 0.000 claims 1
• 229940100389 Sulfonylurea Drugs 0.000 claims 1
• 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 claims 1
• 125000006261 methyl amino sulfonyl group Chemical group [H]N(C([H])([H])[H])S(*)(=O)=O 0.000 claims 1
• BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 1
• 125000004430 oxygen atom Chemical group O* 0.000 claims 1
• 229940044601 receptor agonist Drugs 0.000 claims 1
• 239000000018 receptor agonist Substances 0.000 claims 1
• 230000000694 effects Effects 0.000 abstract description 18
• 230000002265 prevention Effects 0.000 abstract description 10
• 208000023504 respiratory system disease Diseases 0.000 abstract description 7
• 108030003815 Inositol 3-kinases Proteins 0.000 abstract description 6
• 239000002585 base Substances 0.000 description 444
• 239000000543 intermediate Substances 0.000 description 329
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 288
• 238000005481 NMR spectroscopy Methods 0.000 description 163
• 238000004128 high performance liquid chromatography Methods 0.000 description 163
• 239000002253 acid Substances 0.000 description 97
• WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 89
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 85
• 238000007429 general method Methods 0.000 description 82
• QMHIMXFNBOYPND-UHFFFAOYSA-N 4MTO Natural products CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 80
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
• 239000007787 solid Substances 0.000 description 65
• 239000000203 mixture Substances 0.000 description 56
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 44
• 238000006243 chemical reaction Methods 0.000 description 43
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 39
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 37
• 239000002904 solvent Substances 0.000 description 33
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
• 238000000634 powder X-ray diffraction Methods 0.000 description 25
• 238000002360 preparation method Methods 0.000 description 25
• 239000011541 reaction mixture Substances 0.000 description 25
• 230000000873 masking effect Effects 0.000 description 24
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 23
• 235000019439 ethyl acetate Nutrition 0.000 description 22
• 239000012043 crude product Substances 0.000 description 20
• 239000012071 phase Substances 0.000 description 20
• OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 18
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
• 201000010099 disease Diseases 0.000 description 17
• 239000000843 powder Substances 0.000 description 16
• 210000004027 cell Anatomy 0.000 description 15
• 239000013078 crystal Substances 0.000 description 15
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
• 210000001744 T-lymphocyte Anatomy 0.000 description 14
• 239000007858 starting material Substances 0.000 description 14
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
• 102000001708 Protein Isoforms Human genes 0.000 description 13
• 108010029485 Protein Isoforms Proteins 0.000 description 13
• 239000004480 active ingredient Substances 0.000 description 13
• 230000005764 inhibitory process Effects 0.000 description 13
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
• 239000000047 product Substances 0.000 description 13
• 206010028980 Neoplasm Diseases 0.000 description 12
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
• 239000003480 eluent Substances 0.000 description 11
• 239000000243 solution Substances 0.000 description 11
• 239000000725 suspension Substances 0.000 description 11
• 229910004809 Na2 SO4 Inorganic materials 0.000 description 10
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 10
• 229910052794 bromium Inorganic materials 0.000 description 10
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 10
• 210000002540 macrophage Anatomy 0.000 description 10
• 229910052757 nitrogen Inorganic materials 0.000 description 10
• 230000002829 reductive effect Effects 0.000 description 10
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 9
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
• 230000004913 activation Effects 0.000 description 9
• 229910000024 caesium carbonate Inorganic materials 0.000 description 9
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
• 239000003643 water by type Substances 0.000 description 9
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 8
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 8
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 8
• 108091007960 PI3Ks Proteins 0.000 description 8
• 102000038030 PI3Ks Human genes 0.000 description 8
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 8
• 239000000460 chlorine Substances 0.000 description 8
• 229910052801 chlorine Inorganic materials 0.000 description 8
• ASMQGLCHMVWBQR-UHFFFAOYSA-M diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)([O-])OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-M 0.000 description 8
• 239000012044 organic layer Substances 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• 230000011664 signaling Effects 0.000 description 8
• 241000282412 Homo Species 0.000 description 7
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
• 201000011510 cancer Diseases 0.000 description 7
• AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 7
• 210000003979 eosinophil Anatomy 0.000 description 7
• 210000003630 histaminocyte Anatomy 0.000 description 7
• 239000003446 ligand Substances 0.000 description 7
• 210000004072 lung Anatomy 0.000 description 7
• 229960001252 methamphetamine Drugs 0.000 description 7
• 210000000440 neutrophil Anatomy 0.000 description 7
• 239000011734 sodium Substances 0.000 description 7
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• 241001465754 Metazoa Species 0.000 description 6
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
• VOHFRUKPXYDGJC-UHFFFAOYSA-N [O].N1CCNCCC1 Chemical compound [O].N1CCNCCC1 VOHFRUKPXYDGJC-UHFFFAOYSA-N 0.000 description 6
• 238000007792 addition Methods 0.000 description 6
• 229910000288 alkali metal carbonate Inorganic materials 0.000 description 6
• 150000008041 alkali metal carbonates Chemical class 0.000 description 6
• 229910021529 ammonia Inorganic materials 0.000 description 6
• 238000009835 boiling Methods 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 238000004587 chromatography analysis Methods 0.000 description 6
• 229940112141 dry powder inhaler Drugs 0.000 description 6
• 238000010438 heat treatment Methods 0.000 description 6
• 238000001727 in vivo Methods 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• 230000005012 migration Effects 0.000 description 6
• 238000013508 migration Methods 0.000 description 6
• 229910052763 palladium Inorganic materials 0.000 description 6
• 239000002245 particle Substances 0.000 description 6
• 239000003880 polar aprotic solvent Substances 0.000 description 6
• 238000002953 preparative HPLC Methods 0.000 description 6
• 239000003380 propellant Substances 0.000 description 6
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
• 238000010898 silica gel chromatography Methods 0.000 description 6
• 229910052708 sodium Inorganic materials 0.000 description 6
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
• 229910052723 transition metal Inorganic materials 0.000 description 6
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 5
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 5
• 210000003719 b-lymphocyte Anatomy 0.000 description 5
• 230000006378 damage Effects 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 229910052736 halogen Inorganic materials 0.000 description 5
• 150000002367 halogens Chemical class 0.000 description 5
• 230000036039 immunity Effects 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• XHXXWWGGXFUMAJ-UHFFFAOYSA-N methanethiol;sodium Chemical compound [Na].SC XHXXWWGGXFUMAJ-UHFFFAOYSA-N 0.000 description 5
• 239000012074 organic phase Substances 0.000 description 5
• 239000003208 petroleum Substances 0.000 description 5
• 239000000651 prodrug Substances 0.000 description 5
• 229940002612 prodrug Drugs 0.000 description 5
• 125000006239 protecting group Chemical group 0.000 description 5
• 239000000377 silicon dioxide Substances 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 4
• 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 4
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
• 108010012236 Chemokines Proteins 0.000 description 4
• 102000019034 Chemokines Human genes 0.000 description 4
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• 206010020751 Hypersensitivity Diseases 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
• 208000026935 allergic disease Diseases 0.000 description 4
• 235000012538 ammonium bicarbonate Nutrition 0.000 description 4
• 239000001099 ammonium carbonate Substances 0.000 description 4
• 239000000427 antigen Substances 0.000 description 4
• 102000036639 antigens Human genes 0.000 description 4
• 108091007433 antigens Proteins 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 4
• 230000003197 catalytic effect Effects 0.000 description 4
• 238000004090 dissolution Methods 0.000 description 4
• 150000002148 esters Chemical class 0.000 description 4
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 4
• 201000006417 multiple sclerosis Diseases 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
• 238000003756 stirring Methods 0.000 description 4
• 239000004094 surface-active agent Substances 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• 238000012546 transfer Methods 0.000 description 4
• 150000003624 transition metals Chemical class 0.000 description 4
• BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 3
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
• 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 3
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
• 206010011224 Cough Diseases 0.000 description 3
• 206010016654 Fibrosis Diseases 0.000 description 3
• 238000007341 Heck reaction Methods 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• 108010028275 Leukocyte Elastase Proteins 0.000 description 3
• 102000016799 Leukocyte elastase Human genes 0.000 description 3
• 208000019693 Lung disease Diseases 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 3
• XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 3
• 108091000080 Phosphotransferase Proteins 0.000 description 3
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 102000001400 Tryptase Human genes 0.000 description 3
• 108060005989 Tryptase Proteins 0.000 description 3
• 206010047115 Vasculitis Diseases 0.000 description 3
• 208000027418 Wounds and injury Diseases 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 239000000048 adrenergic agonist Substances 0.000 description 3
• 229940126157 adrenergic receptor agonist Drugs 0.000 description 3
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
• 230000000172 allergic effect Effects 0.000 description 3
• 230000007815 allergy Effects 0.000 description 3
• 239000012736 aqueous medium Substances 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 150000001499 aryl bromides Chemical class 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 208000010668 atopic eczema Diseases 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 210000001185 bone marrow Anatomy 0.000 description 3
• 239000012267 brine Substances 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 229910052799 carbon Inorganic materials 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 239000012230 colorless oil Substances 0.000 description 3
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
• 210000004443 dendritic cell Anatomy 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 210000002950 fibroblast Anatomy 0.000 description 3
• 230000004761 fibrosis Effects 0.000 description 3
• 239000000706 filtrate Substances 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 239000007903 gelatin capsule Substances 0.000 description 3
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• 208000014674 injury Diseases 0.000 description 3
• 238000011813 knockout mouse model Methods 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• 229910000069 nitrogen hydride Inorganic materials 0.000 description 3
• 239000007800 oxidant agent Substances 0.000 description 3
• 244000052769 pathogen Species 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 150000003905 phosphatidylinositols Chemical class 0.000 description 3
• 150000003003 phosphines Chemical class 0.000 description 3
• 229910000073 phosphorus hydride Inorganic materials 0.000 description 3
• 102000020233 phosphotransferase Human genes 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 230000000770 proinflammatory effect Effects 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 238000010992 reflux Methods 0.000 description 3
• 206010039083 rhinitis Diseases 0.000 description 3
• 229910000029 sodium carbonate Inorganic materials 0.000 description 3
• 239000007921 spray Substances 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• 150000003573 thiols Chemical class 0.000 description 3
• IXCXVGWKYIDNOS-BYPYZUCNSA-N (1s)-1-cyclopropylethanamine Chemical compound C[C@H](N)C1CC1 IXCXVGWKYIDNOS-BYPYZUCNSA-N 0.000 description 2
• LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
• LLAAHULUUFXMDX-UHFFFAOYSA-N 1-(6-bromopyridin-2-yl)pyrrolidin-2-one Chemical compound BrC1=CC=CC(N2C(CCC2)=O)=N1 LLAAHULUUFXMDX-UHFFFAOYSA-N 0.000 description 2
• RBVQQIHUNZYVTC-UHFFFAOYSA-N 1-[6-[(4-methyl-1,3-thiazol-2-yl)amino]pyridin-2-yl]pyrrolidin-2-one Chemical compound CC1=CSC(NC2=CC=CC(=N2)N2CCCC2=O)=N1 RBVQQIHUNZYVTC-UHFFFAOYSA-N 0.000 description 2
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
• POYLQEKBNAPOBA-UHFFFAOYSA-N 4-(6-bromopyridin-2-yl)morpholin-3-one Chemical compound BrC1=CC=CC(=N1)N1C(COCC1)=O POYLQEKBNAPOBA-UHFFFAOYSA-N 0.000 description 2
• SDZSNMDKZFYOEZ-QMMMGPOBSA-N 5-bromo-2-[(1S)-1-cyclopropylethyl]-7-methylsulfonyl-3H-isoindol-1-one Chemical compound BrC=1C=C2CN(C(C2=C(C=1)S(=O)(=O)C)=O)[C@@H](C)C1CC1 SDZSNMDKZFYOEZ-QMMMGPOBSA-N 0.000 description 2
• ASIQKTWJWGLNOF-ZETCQYMHSA-N 5-bromo-7-chloro-2-[(1s)-1-cyclopropylethyl]-3h-isoindol-1-one Chemical compound C1([C@H](C)N2C(C3=C(Cl)C=C(Br)C=C3C2)=O)CC1 ASIQKTWJWGLNOF-ZETCQYMHSA-N 0.000 description 2
• BKLJUYPLUWUEOQ-UHFFFAOYSA-N 6-bromopyridin-2-amine Chemical compound NC1=CC=CC(Br)=N1 BKLJUYPLUWUEOQ-UHFFFAOYSA-N 0.000 description 2
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 2
• 108091008875 B cell receptors Proteins 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 206010006482 Bronchospasm Diseases 0.000 description 2
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 2
• 201000003883 Cystic fibrosis Diseases 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 206010014561 Emphysema Diseases 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 102000013888 Eosinophil-Derived Neurotoxin Human genes 0.000 description 2
• 108010050456 Eosinophil-Derived Neurotoxin Proteins 0.000 description 2
• OWOHLURDBZHNGG-UHFFFAOYSA-N Hexahydropyrrolo[1,2-a]pyrazine-1,4-dione Chemical compound O=C1CNC(=O)C2CCCN12 OWOHLURDBZHNGG-UHFFFAOYSA-N 0.000 description 2
• 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 description 2
• 108060003951 Immunoglobulin Proteins 0.000 description 2
• 108010002616 Interleukin-5 Proteins 0.000 description 2
• 239000005909 Kieselgur Substances 0.000 description 2
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• SDQPODDUDFEPDG-JTQLQIEISA-N N-[5-[7-chloro-2-[(1S)-1-cyclopropylethyl]-1-oxo-3H-isoindol-5-yl]-4-methyl-1,3-thiazol-2-yl]acetamide Chemical compound C(C)(=O)NC=1SC(=C(N=1)C)C=1C=C2CN(C(C2=C(C=1)Cl)=O)[C@@H](C)C1CC1 SDQPODDUDFEPDG-JTQLQIEISA-N 0.000 description 2
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 108091008611 Protein Kinase B Proteins 0.000 description 2
• 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 238000002441 X-ray diffraction Methods 0.000 description 2
• QWTBREUNMNRQTJ-UHFFFAOYSA-N [O].C1NCC2=CC=CC=C12 Chemical compound [O].C1NCC2=CC=CC=C12 QWTBREUNMNRQTJ-UHFFFAOYSA-N 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• XLAKJQPTOJHYDR-QTQXQZBYSA-M aclidinium bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 XLAKJQPTOJHYDR-QTQXQZBYSA-M 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 201000010105 allergic rhinitis Diseases 0.000 description 2
• 150000001450 anions Chemical class 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 230000007885 bronchoconstriction Effects 0.000 description 2
• 125000004432 carbon atom Chemical group C* 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 150000001768 cations Chemical class 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 230000035605 chemotaxis Effects 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 201000009323 chronic eosinophilic pneumonia Diseases 0.000 description 2
• 208000037976 chronic inflammation Diseases 0.000 description 2
• 230000006020 chronic inflammation Effects 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 108010057085 cytokine receptors Proteins 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000007123 defense Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 238000002050 diffraction method Methods 0.000 description 2
• JZBWUTVDIDNCMW-UHFFFAOYSA-L dipotassium;oxido sulfate Chemical compound [K+].[K+].[O-]OS([O-])(=O)=O JZBWUTVDIDNCMW-UHFFFAOYSA-L 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 230000002327 eosinophilic effect Effects 0.000 description 2
• 230000005496 eutectics Effects 0.000 description 2
• 238000003818 flash chromatography Methods 0.000 description 2
• 235000019253 formic acid Nutrition 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 210000002865 immune cell Anatomy 0.000 description 2
• 102000018358 immunoglobulin Human genes 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 230000004941 influx Effects 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 230000015788 innate immune response Effects 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 210000001165 lymph node Anatomy 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
• 210000003928 nasal cavity Anatomy 0.000 description 2
• 239000006199 nebulizer Substances 0.000 description 2
• 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 2
• 230000000414 obstructive effect Effects 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 230000001590 oxidative effect Effects 0.000 description 2
• 239000003002 pH adjusting agent Substances 0.000 description 2
• LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
• 230000035515 penetration Effects 0.000 description 2
• 150000004965 peroxy acids Chemical class 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 239000012041 precatalyst Substances 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 102000004169 proteins and genes Human genes 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 208000005069 pulmonary fibrosis Diseases 0.000 description 2
• 239000002516 radical scavenger Substances 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000000241 respiratory effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 208000007442 rickets Diseases 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 229910000104 sodium hydride Inorganic materials 0.000 description 2
• 229910052938 sodium sulfate Inorganic materials 0.000 description 2
• 235000011152 sodium sulphate Nutrition 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 150000007944 thiolates Chemical class 0.000 description 2
• 239000008181 tonicity modifier Substances 0.000 description 2
• 210000005090 tracheal smooth muscle Anatomy 0.000 description 2
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
• WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• NBEMORIANHKPTH-GSVOUGTGSA-N (2r)-2-methoxypropanoyl chloride Chemical compound CO[C@H](C)C(Cl)=O NBEMORIANHKPTH-GSVOUGTGSA-N 0.000 description 1
• DIZRUANCFYJHNH-PGMHMLKASA-N (5r)-5-methylpiperazin-2-one;hydrochloride Chemical compound Cl.C[C@@H]1CNC(=O)CN1 DIZRUANCFYJHNH-PGMHMLKASA-N 0.000 description 1
• PVPBBTJXIKFICP-UHFFFAOYSA-N (7-aminophenothiazin-3-ylidene)azanium;chloride Chemical compound [Cl-].C1=CC(=[NH2+])C=C2SC3=CC(N)=CC=C3N=C21 PVPBBTJXIKFICP-UHFFFAOYSA-N 0.000 description 1
• KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
• SNZHLQGVNUAJTN-UHFFFAOYSA-N 1-(6-bromopyridin-2-yl)imidazolidin-2-one Chemical compound BrC1=CC=CC(N2C(NCC2)=O)=N1 SNZHLQGVNUAJTN-UHFFFAOYSA-N 0.000 description 1
• 238000005160 1H NMR spectroscopy Methods 0.000 description 1
• VQSJAWPFQCXIOB-VODLGYORSA-N 2,3-dihydroxypropyl [(1r,2r,3s,4r,5r,6s)-2,3,6-trihydroxy-4,5-diphosphonooxycyclohexyl] hydrogen phosphate Chemical compound OCC(O)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O VQSJAWPFQCXIOB-VODLGYORSA-N 0.000 description 1
• FEYDZHNIIMENOB-UHFFFAOYSA-N 2,6-dibromopyridine Chemical compound BrC1=CC=CC(Br)=N1 FEYDZHNIIMENOB-UHFFFAOYSA-N 0.000 description 1
• DMIIPYYADLDKAX-HNNXBMFYSA-N 2-[(1S)-1-cyclopropylethyl]-5-[4-methyl-2-[[6-(2-oxoimidazolidin-1-yl)pyridin-2-yl]amino]-1,3-thiazol-5-yl]-7-methylsulfonyl-3H-isoindol-1-one Chemical compound C[C@@H](C1CC1)N1CC2=CC(=CC(=C2C1=O)S(C)(=O)=O)C1=C(C)N=C(NC2=NC(=CC=C2)N2CCNC2=O)S1 DMIIPYYADLDKAX-HNNXBMFYSA-N 0.000 description 1
• BHFJVMZATJXYCO-KRWDZBQOSA-N 2-[(1S)-1-cyclopropylethyl]-6-[4-methyl-2-[[6-(2-oxopyrrolidin-1-yl)pyridin-2-yl]amino]-1,3-thiazol-5-yl]-N-(oxetan-3-yl)-3-oxo-1H-isoindole-4-sulfonamide Chemical compound C1(CC1)[C@H](C)N1CC=2C=C(C=C(C=2C1=O)S(=O)(=O)NC1COC1)C1=C(N=C(S1)NC1=NC(=CC=C1)N1C(CCC1)=O)C BHFJVMZATJXYCO-KRWDZBQOSA-N 0.000 description 1
• ZGQXHYGEONUMTE-KRWDZBQOSA-N 2-[(1S)-1-cyclopropylethyl]-6-[4-methyl-2-[[6-(3-oxomorpholin-4-yl)pyridin-2-yl]amino]-1,3-thiazol-5-yl]-N-(oxetan-3-yl)-3-oxo-1H-isoindole-4-sulfonamide Chemical compound C1(CC1)[C@H](C)N1CC=2C=C(C=C(C=2C1=O)S(=O)(=O)NC1COC1)C1=C(N=C(S1)NC1=NC(=CC=C1)N1C(COCC1)=O)C ZGQXHYGEONUMTE-KRWDZBQOSA-N 0.000 description 1
• TYTHLOGWHWLWET-WBVHZDCISA-N 2-[(1S)-1-cyclopropylethyl]-N-methyl-6-[4-methyl-2-[[6-[(2R)-2-methyl-6-oxopiperazin-1-yl]pyridin-2-yl]amino]-1,3-thiazol-5-yl]-3-oxo-1H-isoindole-4-sulfonamide Chemical compound C1(CC1)[C@H](C)N1CC=2C=C(C=C(C=2C1=O)S(=O)(=O)NC)C1=C(N=C(S1)NC1=NC(=CC=C1)N1[C@@H](CNCC1=O)C)C TYTHLOGWHWLWET-WBVHZDCISA-N 0.000 description 1
• KRJCGMRLWBVONG-IRXDYDNUSA-N 2-[(1S)-1-cyclopropylethyl]-N-methyl-6-[4-methyl-2-[[6-[(3S)-3-methyl-2-oxopiperazin-1-yl]pyridin-2-yl]amino]-1,3-thiazol-5-yl]-3-oxo-1H-isoindole-4-sulfonamide Chemical compound C1(CC1)[C@H](C)N1CC=2C=C(C=C(C=2C1=O)S(=O)(=O)NC)C1=C(N=C(S1)NC1=NC(=CC=C1)N1C([C@@H](NCC1)C)=O)C KRJCGMRLWBVONG-IRXDYDNUSA-N 0.000 description 1
• YXGZTQDPLYDOCC-WBVHZDCISA-N 2-[(1S)-1-cyclopropylethyl]-N-methyl-6-[4-methyl-2-[[6-[(5R)-5-methyl-2-oxopiperazin-1-yl]pyridin-2-yl]amino]-1,3-thiazol-5-yl]-3-oxo-1H-isoindole-4-sulfonamide Chemical compound C1(CC1)[C@H](C)N1CC=2C=C(C=C(C=2C1=O)S(=O)(=O)NC)C1=C(N=C(S1)NC1=NC(=CC=C1)N1C(CN[C@@H](C1)C)=O)C YXGZTQDPLYDOCC-WBVHZDCISA-N 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
• VLRSVMBPXWKSNE-INIZCTEOSA-N 4-[6-[[5-[2-[(1S)-1-cyclopropylethyl]-7-methylsulfonyl-1-oxo-3H-isoindol-5-yl]-4-methyl-1,3-thiazol-2-yl]amino]pyridin-2-yl]morpholin-3-one Chemical compound C1(CC1)[C@H](C)N1C(C2=C(C=C(C=C2C1)C1=C(N=C(S1)NC1=NC(=CC=C1)N1C(COCC1)=O)C)S(=O)(=O)C)=O VLRSVMBPXWKSNE-INIZCTEOSA-N 0.000 description 1
• SQTLUXJWUCHKMT-UHFFFAOYSA-N 4-bromo-n,n-diphenylaniline Chemical compound C1=CC(Br)=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 SQTLUXJWUCHKMT-UHFFFAOYSA-N 0.000 description 1
• LRTRXDSAJLSRTG-UHFFFAOYSA-N 4-bromobutanoyl chloride Chemical compound ClC(=O)CCCBr LRTRXDSAJLSRTG-UHFFFAOYSA-N 0.000 description 1
• OUQMXTJYCAJLGO-UHFFFAOYSA-N 4-methyl-1,3-thiazol-2-amine Chemical compound CC1=CSC(N)=N1 OUQMXTJYCAJLGO-UHFFFAOYSA-N 0.000 description 1
• RKQRQLJUZPFRIG-ZETCQYMHSA-N 5,7-dichloro-2-[(1S)-1-cyclopropylethyl]-3H-isoindol-1-one Chemical compound C[C@@H](C1CC1)N1CC2=CC(Cl)=CC(Cl)=C2C1=O RKQRQLJUZPFRIG-ZETCQYMHSA-N 0.000 description 1
• KGCVZPWGIKNFID-JTQLQIEISA-N 5-(2-amino-4-methyl-1,3-thiazol-5-yl)-2-[(1S)-1-cyclopropylethyl]-7-methylsulfonyl-3H-isoindol-1-one Chemical compound NC=1SC(=C(N=1)C)C=1C=C2CN(C(C2=C(C=1)S(=O)(=O)C)=O)[C@@H](C)C1CC1 KGCVZPWGIKNFID-JTQLQIEISA-N 0.000 description 1
• BMEVMMHSZQHXGB-ZDUSSCGKSA-N 5-[4-methyl-2-[[6-(2-oxoimidazolidin-1-yl)pyridin-2-yl]amino]-1,3-thiazol-5-yl]-7-methylsulfonyl-2-[(2S)-1,1,1-trifluoropropan-2-yl]-3H-isoindol-1-one Chemical compound CC=1N=C(SC=1C=1C=C2CN(C(C2=C(C=1)S(=O)(=O)C)=O)[C@H](C(F)(F)F)C)NC1=NC(=CC=C1)N1C(NCC1)=O BMEVMMHSZQHXGB-ZDUSSCGKSA-N 0.000 description 1
• SJGQDAOATLQSOP-QMMMGPOBSA-N 5-bromo-2-[(1S)-1-cyclopropylethyl]-7-methylsulfanyl-3H-isoindol-1-one Chemical compound CSC1=C2C(CN([C@@H](C)C3CC3)C2=O)=CC(Br)=C1 SJGQDAOATLQSOP-QMMMGPOBSA-N 0.000 description 1
• JIUNWGJWEONLHV-ZETCQYMHSA-N 5-chloro-2-[(1S)-1-cyclopropylethyl]-7-fluoro-3H-isoindol-1-one Chemical compound C[C@@H](C1CC1)N1CC2=C(C1=O)C(F)=CC(Cl)=C2 JIUNWGJWEONLHV-ZETCQYMHSA-N 0.000 description 1
• QODUBKLOLIXIHV-QMMMGPOBSA-N 5-chloro-2-[(1S)-1-cyclopropylethyl]-7-methylsulfanyl-3H-isoindol-1-one Chemical compound CSC1=C2C(CN([C@@H](C)C3CC3)C2=O)=CC(Cl)=C1 QODUBKLOLIXIHV-QMMMGPOBSA-N 0.000 description 1
• DNXRADLJFQLRJR-QMMMGPOBSA-N 5-chloro-2-[(1S)-1-cyclopropylethyl]-7-methylsulfonyl-3H-isoindol-1-one Chemical compound C[C@@H](C1CC1)N1CC2=CC(Cl)=CC(=C2C1=O)S(C)(=O)=O DNXRADLJFQLRJR-QMMMGPOBSA-N 0.000 description 1
• ZAWKCTQNKKDNMQ-YJBOKZPZSA-N 6-[2-[[6-[(3S)-3-hydroxy-2-oxopyrrolidin-1-yl]pyridin-2-yl]amino]-4-methyl-1,3-thiazol-5-yl]-3-oxo-N-propan-2-yl-2-[(2S)-1,1,1-trifluoropropan-2-yl]-1H-isoindole-4-sulfonamide Chemical compound O[C@@H]1C(N(CC1)C1=CC=CC(=N1)NC=1SC(=C(N=1)C)C=1C=C(C=2C(N(CC=2C=1)[C@H](C(F)(F)F)C)=O)S(=O)(=O)NC(C)C)=O ZAWKCTQNKKDNMQ-YJBOKZPZSA-N 0.000 description 1
• HXALBTBBYYKFPZ-KRWDZBQOSA-N 6-[6-[[5-[2-[(1S)-1-cyclopropylethyl]-7-methylsulfonyl-1-oxo-3H-isoindol-5-yl]-4-methyl-1,3-thiazol-2-yl]amino]pyridin-2-yl]-7H-pyrrolo[3,4-b]pyridin-5-one Chemical compound C1(CC1)[C@H](C)N1C(C2=C(C=C(C=C2C1)C1=C(N=C(S1)NC1=CC=CC(=N1)N1CC2=NC=CC=C2C1=O)C)S(=O)(=O)C)=O HXALBTBBYYKFPZ-KRWDZBQOSA-N 0.000 description 1
• GXWNSJYVSIJRLS-UHFFFAOYSA-N 6-bromo-8-methylimidazo[1,2-a]pyrazine Chemical compound CC1=NC(Br)=CN2C=CN=C12 GXWNSJYVSIJRLS-UHFFFAOYSA-N 0.000 description 1
• LYEPZCPAEZKSKN-UHFFFAOYSA-N 6-bromo-n-methylpyridin-2-amine Chemical compound CNC1=CC=CC(Br)=N1 LYEPZCPAEZKSKN-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 206010001889 Alveolitis Diseases 0.000 description 1
• 208000035939 Alveolitis allergic Diseases 0.000 description 1
• 102000006306 Antigen Receptors Human genes 0.000 description 1
• 108010083359 Antigen Receptors Proteins 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 241001132374 Asta Species 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• ORFPJTPFEMTFQR-UHFFFAOYSA-N BrC1=CC(=C(C(=O)O)C(=C1)Cl)CBr Chemical compound BrC1=CC(=C(C(=O)O)C(=C1)Cl)CBr ORFPJTPFEMTFQR-UHFFFAOYSA-N 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 206010006473 Bronchopulmonary aspergillosis Diseases 0.000 description 1
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
• PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 1
• 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• 108010059108 CD18 Antigens Proteins 0.000 description 1
• 101150013553 CD40 gene Proteins 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 108090000746 Chymosin Proteins 0.000 description 1
• 108091007962 Class I PI3K catalytic Proteins 0.000 description 1
• 241000711573 Coronaviridae Species 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 206010065563 Eosinophilic bronchitis Diseases 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 208000027445 Farmer Lung Diseases 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
• 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
• 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
• 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
• 108010022222 Integrin beta1 Proteins 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 210000004322 M2 macrophage Anatomy 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
• 239000012901 Milli-Q water Substances 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• LHKIAELCKQHVBI-NSHDSACASA-N N-[5-[2-[(1S)-1-cyclopropylethyl]-7-(methylsulfamoyl)-1-oxo-3H-isoindol-5-yl]-4-methyl-1,3-thiazol-2-yl]acetamide Chemical compound CNS(=O)(=O)c1cc(cc2CN([C@@H](C)C3CC3)C(=O)c12)-c1sc(NC(C)=O)nc1C LHKIAELCKQHVBI-NSHDSACASA-N 0.000 description 1
• ZQAQRSMPZMVHIQ-INIZCTEOSA-N N-[5-[7-benzylsulfanyl-2-[(1S)-1-cyclopropylethyl]-1-oxo-3H-isoindol-5-yl]-4-methyl-1,3-thiazol-2-yl]acetamide Chemical compound C(C)(=O)NC=1SC(=C(N=1)C)C=1C=C2CN(C(C2=C(C=1)SCC1=CC=CC=C1)=O)[C@@H](C)C1CC1 ZQAQRSMPZMVHIQ-INIZCTEOSA-N 0.000 description 1
• FLUPYHUXCIWKAE-KRWDZBQOSA-N N-[6-[[5-[2-[(1S)-1-cyclopropylethyl]-7-(methylsulfamoyl)-1-oxo-3H-isoindol-5-yl]-4-methyl-1,3-thiazol-2-yl]amino]pyridin-2-yl]-2-ethoxy-N-methylacetamide Chemical compound C1(CC1)[C@H](C)N1C(C2=C(C=C(C=C2C1)C1=C(N=C(S1)NC1=CC=CC(=N1)N(C(COCC)=O)C)C)S(NC)(=O)=O)=O FLUPYHUXCIWKAE-KRWDZBQOSA-N 0.000 description 1
• YAOHUGMVFAJBNE-INIZCTEOSA-N N-[6-[[5-[2-[(1S)-1-cyclopropylethyl]-7-(methylsulfamoyl)-1-oxo-3H-isoindol-5-yl]-4-methyl-1,3-thiazol-2-yl]amino]pyridin-2-yl]-2-methoxy-N-methylacetamide Chemical compound C1(CC1)[C@H](C)N1C(C2=C(C=C(C=C2C1)C1=C(N=C(S1)NC1=CC=CC(=N1)N(C(COC)=O)C)C)S(NC)(=O)=O)=O YAOHUGMVFAJBNE-INIZCTEOSA-N 0.000 description 1
• KWHLMLQDUKNHBO-HNNXBMFYSA-N N-[6-[[5-[2-[(1S)-1-cyclopropylethyl]-7-methylsulfonyl-1-oxo-3H-isoindol-5-yl]-4-methyl-1,3-thiazol-2-yl]amino]pyridin-2-yl]-N-methylacetamide Chemical compound C[C@@H](C1CC1)N1CC2=CC(=CC(=C2C1=O)S(C)(=O)=O)C1=C(C)N=C(NC2=CC=CC(=N2)N(C)C(C)=O)S1 KWHLMLQDUKNHBO-HNNXBMFYSA-N 0.000 description 1
• 208000000592 Nasal Polyps Diseases 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 102100032341 PCNA-interacting partner Human genes 0.000 description 1
• 101710196737 PCNA-interacting partner Proteins 0.000 description 1
• 101150037263 PIP2 gene Proteins 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 208000004430 Pulmonary Aspergillosis Diseases 0.000 description 1
• MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 241000725643 Respiratory syncytial virus Species 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 206010039094 Rhinitis perennial Diseases 0.000 description 1
• 208000036284 Rhinitis seasonal Diseases 0.000 description 1
• OLINNIZIAJWIFH-UHFFFAOYSA-N S(=O)(=O)(O)C1=C(C=2CC3=CC=CC=C3C2C=C1)Cl Chemical compound S(=O)(=O)(O)C1=C(C=2CC3=CC=CC=C3C2C=C1)Cl OLINNIZIAJWIFH-UHFFFAOYSA-N 0.000 description 1
• 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
• 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
• 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• 208000019802 Sexually transmitted disease Diseases 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 102000002689 Toll-like receptor Human genes 0.000 description 1
• 108020000411 Toll-like receptor Proteins 0.000 description 1
• 208000027515 Tracheal disease Diseases 0.000 description 1
• 206010065899 Tracheal inflammation Diseases 0.000 description 1
• 206010044302 Tracheitis Diseases 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
• 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
• MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 238000010306 acid treatment Methods 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 206010069351 acute lung injury Diseases 0.000 description 1
• 210000005006 adaptive immune system Anatomy 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 230000009285 allergic inflammation Effects 0.000 description 1
• 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
• 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
• 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
• 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 150000001409 amidines Chemical class 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000001772 anti-angiogenic effect Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• 229940124748 beta 2 agonist Drugs 0.000 description 1
• 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 239000000227 bioadhesive Substances 0.000 description 1
• KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
• 239000004327 boric acid Substances 0.000 description 1
• 201000009267 bronchiectasis Diseases 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 229940124630 bronchodilator Drugs 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• WOBLPDAWNVAVAS-UHFFFAOYSA-N butyl carboxy carbonate Chemical compound CCCCOC(=O)OC(O)=O WOBLPDAWNVAVAS-UHFFFAOYSA-N 0.000 description 1
• DLIJPAHLBJIQHE-UHFFFAOYSA-N butylphosphane Chemical compound CCCCP DLIJPAHLBJIQHE-UHFFFAOYSA-N 0.000 description 1
• 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000009087 cell motility Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 230000009920 chelation Effects 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 239000012320 chlorinating reagent Substances 0.000 description 1
• 150000001805 chlorine compounds Chemical class 0.000 description 1
• KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
• 208000013116 chronic cough Diseases 0.000 description 1
• 201000009151 chronic rhinitis Diseases 0.000 description 1
• 229940080701 chymosin Drugs 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 210000003690 classically activated macrophage Anatomy 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 210000000795 conjunctiva Anatomy 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000000586 desensitisation Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 239000000428 dust Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000029578 entry into host Effects 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 238000001952 enzyme assay Methods 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• XMBFQAGQWNLLEZ-UHFFFAOYSA-N ethanimidamide methanamine Chemical compound CN.C(C)(=N)N XMBFQAGQWNLLEZ-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• 208000022195 farmer lung disease Diseases 0.000 description 1
• KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000003209 gene knockout Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 229940046528 grass pollen Drugs 0.000 description 1
• 230000005484 gravity Effects 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 125000004404 heteroalkyl group Chemical group 0.000 description 1
• 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
• 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
• 239000008214 highly purified water Substances 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
• IKGLACJFEHSFNN-UHFFFAOYSA-N hydron;triethylazanium;trifluoride Chemical compound F.F.F.CCN(CC)CC IKGLACJFEHSFNN-UHFFFAOYSA-N 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 230000000642 iatrogenic effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000008629 immune suppression Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 239000011261 inert gas Substances 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 210000005007 innate immune system Anatomy 0.000 description 1
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 239000012948 isocyanate Substances 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 150000003951 lactams Chemical class 0.000 description 1
• 239000000832 lactitol Substances 0.000 description 1
• VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
• 235000010448 lactitol Nutrition 0.000 description 1
• 229960003451 lactitol Drugs 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
• 239000000845 maltitol Substances 0.000 description 1
• 235000010449 maltitol Nutrition 0.000 description 1
• 229940035436 maltitol Drugs 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 229960001855 mannitol Drugs 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
• 230000004089 microcirculation Effects 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 210000000651 myofibroblast Anatomy 0.000 description 1
• GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
• DPDJXTANWGNJOE-UHFFFAOYSA-N n-(4-methyl-1,3-thiazol-2-yl)acetamide Chemical compound CC(=O)NC1=NC(C)=CS1 DPDJXTANWGNJOE-UHFFFAOYSA-N 0.000 description 1
• ROJDZKLSUROPIP-UHFFFAOYSA-N n-(6-bromopyridin-2-yl)-n-methylacetamide Chemical compound CC(=O)N(C)C1=CC=CC(Br)=N1 ROJDZKLSUROPIP-UHFFFAOYSA-N 0.000 description 1
• AZKOTMZRXXAOOB-UHFFFAOYSA-N n-(6-bromopyridin-2-yl)acetamide Chemical compound CC(=O)NC1=CC=CC(Br)=N1 AZKOTMZRXXAOOB-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• UYKPFQRPPLZHDD-UHFFFAOYSA-N n-chloro-2-methoxyacetamide Chemical compound COCC(=O)NCl UYKPFQRPPLZHDD-UHFFFAOYSA-N 0.000 description 1
• OHLUUHNLEMFGTQ-DYCDLGHISA-N n-deuterio-n-methylacetamide Chemical compound [2H]N(C)C(C)=O OHLUUHNLEMFGTQ-DYCDLGHISA-N 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 201000009240 nasopharyngitis Diseases 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
• PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 description 1
• 208000022719 perennial allergic rhinitis Diseases 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
• 150000003906 phosphoinositides Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 230000000865 phosphorylative effect Effects 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000010287 polarization Effects 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
• HDMGAZBPFLDBCX-UHFFFAOYSA-N potassium;sulfooxy hydrogen sulfate Chemical compound [K+].OS(=O)(=O)OOS(O)(=O)=O HDMGAZBPFLDBCX-UHFFFAOYSA-N 0.000 description 1
• 238000003825 pressing Methods 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
• 208000002815 pulmonary hypertension Diseases 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
• 239000003642 reactive oxygen metabolite Substances 0.000 description 1
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 229940108461 rennet Drugs 0.000 description 1
• 108010058314 rennet Proteins 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 229940072265 rhinocort Drugs 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000007727 signaling mechanism Effects 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 239000012265 solid product Substances 0.000 description 1
• 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 239000011877 solvent mixture Substances 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 238000012306 spectroscopic technique Methods 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 239000012089 stop solution Substances 0.000 description 1
• 210000003537 structural cell Anatomy 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 229960004793 sucrose Drugs 0.000 description 1
• 238000000967 suction filtration Methods 0.000 description 1
• 150000005846 sugar alcohols Chemical class 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 230000007838 tissue remodeling Effects 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 229940074410 trehalose Drugs 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 208000001319 vasomotor rhinitis Diseases 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 239000004034 viscosity adjusting agent Substances 0.000 description 1
• QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
• QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
• 229940075420 xanthine Drugs 0.000 description 1